TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06165692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: Post-operative PRF placement in the post-extraction socket after third molar surgery
Study: NCT06019117

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic K10
Description: clinical trial using 90 days of probiotic K10

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic K10
Description: clinical trial using 90 days of probiotic K10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: clinical trial using 90 days of placebo controlled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: clinical trial using 90 days of placebo controlled
Study: NCT05283330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ²¹²Pb-DOTAM-GRPR1
Description: ²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
Study: NCT05783037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Organic Infant Formula
Description: New organic infant formula fed daily ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Organic Infant Formula
Description: Commercially available organic infant formula fed daily ad libitum
Study: NCT04983342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Armband
Description: The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
Study: NCT05487391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05718531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet twice daily
Description: effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet twice daily
Description: effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet twice daily
Description: effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Used as control group in 2nd arm and 5th arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Used as control group in 2nd arm and 5th arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Used as control group in 2nd arm and 5th arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Used as control group in 2nd arm and 5th arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet 75 mg
Description: Used as control group in 2nd arm and 5th arm
Study: NCT06368739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurture program
Description: 1. Nurture Monthly Packages: Sent every four weeks until the member reaches the end of pregnancy (delivery or other reasons, e.g., miscarriage), with a maximum of eight packages. Each package includes:~   * A US$40 gift card (2 x $20 each) to a grocery store.~  * A healthy eating information sheet selected from Brighter Bites project (https://brighterbites.org/).~  * A set of three recipes.~  * Nutrition-related Frequently Asked Questions (included in four out of the eight packages).~2. Two 30-Minute Nutritional Consultations over the phone: Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular benefits
Description: Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular benefits
Description: Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.
Study: NCT05913427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
Study: NCT06421428

Intervention type: OTHER
Intervention: LEI Interview
Description: In accordance with the IPA (Interpretative phenomenological analysis) methodology, a semi-structured interview outline will be defined, aimed at understanding the lived experiences of women (lived experience) during their coexistence with urinary incontinence and during the treatment process.~The screwdriver questions were formulated starting from the reference literature and will be discussed in a focus group composed of a uro-gynecologist, two midwives, a nurse, an expert in qualitative methodology. The final screwdriver questions resulting from the focus group will be tested on a small group of women.

Intervention type: OTHER
Intervention: LEI Survey
Description: Some sociodemographic data identified from the reference literature will be collected in paper form immediately at the end of each interview, for the description of the sample. The data will concern: age, nationality, marital status, level of education, number of children, menopause, social relationships, level of information, period of onset of symptoms, type of symptomatology, frequency of episodes of urinary incontinence, quantity of urinary leakage, uro-gynecological pathological history.
Study: NCT06538181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.
Study: NCT05718531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet 75 mg
Description: Used as control group in 2nd arm and 5th arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet 75 mg
Description: Used as control group in 2nd arm and 5th arm
Study: NCT05997550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pursed Lip Breathing Exercise
Description: Pursed Lip Breathing Exercise for The COPD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laughter Therapy
Description: Laughter Therapy for the COPD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the control group.
Description: Attention-match training is given to the patients in the control group.
Study: NCT05147935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: In person or telehealth clinic visit with palliative care physician or nurse practitioner
Study: NCT06340516

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP
Description: Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity
Study: NCT06149026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and nutritional therapy
Description: The patients will be evaluated and followed by a nutritionist and a physical therapist for 12 weeks. In that time, the patients will receive workouts according to their evaluations and a specific nutritional guide according to the nutritionist's evaluations.
Study: NCT05592262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: On an empty stomach - after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: After meals - on an empty stomach
Study: NCT04622293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol Oral Tablet [Sunosi]
Description: Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
Study: NCT05608499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii
Description: topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical does not contain active properties of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryhali
Description: Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
Study: NCT06428786

Intervention type: OTHER
Intervention: Female Sexual Function Index
Description: As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.

Intervention type: OTHER
Intervention: Female Sexual Function Index
Description: As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.

Intervention type: OTHER
Intervention: Female Sexual Function Index
Description: As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.

Intervention type: OTHER
Intervention: Female Sexual Function Index
Description: As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.
Study: NCT06227338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg).
Study: NCT05680012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten containing snack bar
Description: Ingest snack bars containing 3 grams of gluten every day for 6 weeks.
Study: NCT06104657

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05962385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain state while receiving TMS
Description: Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
Study: NCT05735847

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty (TKA)
Description: The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.

Intervention type: PROCEDURE
Intervention: Unicompartmental Knee Arthroplasty (UKA)
Description: The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
Study: NCT06277817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiratory rib cage compression
Description: Expiratory rib cage compression: The hands are placed on the lower third of the rib cage. During expiration, the end and sides of the patients' rib cage are gradually compressed with the hands.At the end of expiration, compression is released from the thorax to allow patients to take a free inspiration. After each compression, the patient is allowed to perform 3 breathing cycles.Expiratory rib cage compression is applied for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: percussion vibration
Description: Percussion :Percussion is performed 3-5 times on each area from a height of approximately 10 cm with the domed hand. . It starts from the right and left lower lobes and goes up.Vibration:The hand is firmly/strongly placed on the application area. The arm and shoulder are stretched and the fingers are gently vibrated or shaken gently. While the patient is exhaling, vibration is performed 3-5 times in each area, starting from the right and left lower lobes.
Study: NCT05161403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: honey
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: honey
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: honey
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.
Study: NCT05921409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention
Description: This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil-supplemented Mediterranean Diet Intervention
Description: This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded.
Study: NCT05921006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJ4287
Description: Oral，tablets，Once daily for 14 days
Study: NCT05701618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychologically Informed Education Video Series
Description: A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anatomy and biomedical education videos
Description: Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.